home / stock / pavmz / pavmz news

PAVMZ News and Press, PAVmed Inc. Series Z Warrant From 07/22/21

Stock Information
Company Name: PAVmed Inc. Series Z Warrant
Stock Symbol: PAVMZ
Market: NASDAQ
Website: pavmed.com
Menu
PAVMZ PAVMZ Quote PAVMZ Short PAVMZ News PAVMZ Articles PAVMZ Message Board
Get PAVMZ Alerts

News, Short Squeeze, Breakout and More Instantly...
PAVMZ - PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth

UpScriptHealth to provide telemedicine services to evaluate consumers with chronic heartburn seeking early esophageal precancer detection using Lucid’s EsoGuard test PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a high...
PAVMZ - Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology ind...

PAVMZ - PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), has comple...

PAVMZ - PAVmed Launches Digital Health Company Veris Health Inc.

New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. Technologies include first intelligent implantable vascular access port with biologic sensors and wireless communication combined with rem...
PAVMZ - PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid&#x...

PAVMZ - PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its Carp...

PAVMZ - Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics' EsoCheck and EsoGuard Technologies

Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed&#...
PAVMZ - PAVmed Provides Business Update and First Quarter 2021 Financial Results

Conference call to be held today at 4 :30 P M E D T NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical d...

PAVMZ - PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021

Dr. David Poppers to present on his initial experience with Lucid’s EsoCheck and EsoGuard NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, comm...

PAVMZ - PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team

Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed” or the “Company”), a hi...
Previous 10 Next 10